A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

August 29, 2016

Primary Completion Date

October 10, 2018

Study Completion Date

April 3, 2019

Conditions
Neoplasm Metastasis
Interventions
DRUG

Olaratumab

Olaratumab administered IV.

DRUG

Doxorubicin

Doxorubicin administered IV.

DRUG

Vincristine

Vincristine administered IV.

DRUG

Irinotecan

Irinotecan administered IV.

DRUG

Ifosfamide

Ifosfamide administered IV.

Trial Locations (21)

10065

Memorial Sloan Kettering Cancer Center, New York

11040

Cohen Children's Medical Center, New Hyde Park

28203

Levine Children's Hospital, Charlotte

33136

Sylvester Comprehensive Cancer Center, Miami

38105

St Jude Childrens Research Hospital, Memphis

46202

Riley Hosptial for Children, Indianapolis

55455

University of Minnesota Medical School, Minneapolis

64108

Children's Mercy Hospital, Kansas City

75230

Mary Crowley Cancer Research Center, Dallas

75235

University of Texas Southwestern Medical Center at Dallas, Dallas

77030

Texas Childrens Hospital, Houston

80045

The Children's Hospital for Cancer and Blood Disorders, Aurora

84132

Primary Childrens Medical Center, Salt Lake City

85016

Phoenix Childrens Hospital, Phoenix

90027

Childrens Hospital of Los Angeles, Los Angeles

94158

University of California, San Francisco, San Francisco

98105

Seattle Children's Hospital Research Foundation, Seattle

20010-2970

Children's National Medical Center, Washington D.C.

02115

Dana Farber Cancer Institute, Boston

37232-6307

Vanderbilt University Medical Center, Nashville

104-0045

National Cancer Center Hospital, Chuo-Ku

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02677116 - A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer | Biotech Hunter | Biotech Hunter